Your browser doesn't support javascript.
loading
Omicron breakthrough infections after triple-dose inactivated COVID-19 vaccination: A comprehensive analysis of antibody and T-cell responses.
Xiang, Tiandan; Quan, Xufeng; Jia, Hang; Wang, Hua; Liang, Boyun; Li, Sumeng; Wang, Xiaoyan; Li, Huadong; Feng, Xuemei; Fan, Lei; Xu, Ling; Wang, Tong; Xiong, Shue; Yang, Dongliang; Liu, Jia; Zheng, Xin.
  • Xiang T; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Quan X; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.
  • Jia H; Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Wang H; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Liang B; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.
  • Li S; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang X; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.
  • Li H; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Feng X; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.
  • Fan L; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Xu L; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.
  • Wang T; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Xiong S; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.
  • Yang D; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Liu J; Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.
  • Zheng X; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Immunology ; 172(2): 313-327, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38462236
ABSTRACT
This study longitudinally evaluated the immune response in individuals over a year after receiving three doses of an inactivated SARS-CoV-2 vaccine, focusing on reactions to Omicron breakthrough infections. From 63 blood samples of 37 subjects, results showed that the third booster enhanced the antibody response against Alpha, Beta, and Delta VOCs but was less effective against Omicron. Although antibody titres decreased post-vaccination, SARS-CoV-2-specific T-cell responses, both CD4+ and CD8+, remained stable. Omicron breakthrough infections significantly improved neutralization against various VOCs, including Omicron. However, the boost in antibodies against WT, Alpha, Beta, and Delta variants was more pronounced. Regarding T cells, breakthrough infection predominantly boosted the CD8+ T-cell response, and the intensity of the spike protein-specific T-cell response was roughly comparable between WT and Omicron BA.5.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 / Infección Irruptiva / Anticuerpos Antivirales Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 / Infección Irruptiva / Anticuerpos Antivirales Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2024 Tipo del documento: Article